XML 43 R24.htm IDEA: XBRL DOCUMENT
v3.26.1

SEGMENT REPORTING | 12 Months Ended
--- | ---
Dec. 31, 2025
Disclosure of operating segments [abstract] |
SEGMENT REPORTING | NOTE 19 – SEGMENT REPORTING The Company operates in a single reportable operating segment – the development and commercialization of therapeutics. Its corporate headquarters and development activities are in Israel, while its revenues stem from activities carried out in the U.S. and Asia (primarily Greater China). In this regard, product sales relate to the Company’s direct commercialization activities in the U.S. from October 2023 through November 2024, while license revenues relate to outlicensing agreements entered into in Asia and in the U.S. in October 2023 and November 2024, respectively. Set forth below is a breakdown of revenues from external parties by geographic region.
|  | Year ended December 31, |
|  | 2023 |  |  | 2024 |  |  | 2025 |
|  | in USD thousands |
China |  |  | 4,610 |  |  |  | 14,957 |  |  |  | - |
U.S. |  |  | 190 |  |  |  | 13,983 |  |  |  | 1,180 |
|  |  | 4,800 |  |  |  | 28,940 |  |  |  | 1,180 |
Substantially all of the Company’s non-current assets are located in Israel. See Notes 15 and 16 for information on customers representing 10% or more of total revenues.

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of operating segments. [Refer: Operating segments [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2025-01-01 -Paragraph 23 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration